Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.445
-0.085 (-1.88%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Precigen Revenue
Precigen had revenue of $23.25M in the quarter ending March 31, 2026, with 1,633.93% growth. This brings the company's revenue in the last twelve months to $31.60M, up 652.08% year-over-year. In the year 2025, Precigen had annual revenue of $9.68M with 146.73% growth.
Revenue (ttm)
$31.60M
Revenue Growth
+652.08%
P/S Ratio
50.10
Revenue / Employee
$197,469
Employees
160
Market Cap
1.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.68M | 5.76M | 146.73% |
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -88.91M | -86.17% |
| Dec 31, 2020 | 103.18M | 12.46M | 13.73% |
| Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
| Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
| Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
| Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
| Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
| Dec 31, 2014 | 71.93M | 71.13M | 8,891.25% |
| Dec 31, 2013 | 800.00K | -12.97M | -94.19% |
| Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
| Dec 31, 2011 | 8.01M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 427.68M |
| Maravai LifeSciences Holdings | 204.73M |
| UroGen Pharma | 140.49M |
| Septerna | 72.26M |
| Maze Therapeutics | 20.00M |
| Inhibrx Biosciences | 1.30M |
PGEN News
- 1 day ago - Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices - PRNewsWire
- 4 days ago - Precigen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 11 days ago - Precigen presents long-term follow-up data from study of Papzimeos - TheFly
- 13 days ago - Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years - PRNewsWire
- 15 days ago - Precigen price target raised to $14 from $11 at H.C. Wainwright - TheFly
- 16 days ago - Precigen receives orphan drug exclusivity for papzimeos in the U.S. - TheFly
- 16 days ago - Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States - PRNewsWire
- 17 days ago - Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference - PRNewsWire